Time filter

Source Type

Jia W.,The Provincial Hospital of Anhui | Feng K.,Anhui Tumor Hospital | Fan P.,Anhui Tumor Hospital | Fan G.,Anhui Tumor Hospital | And 4 more authors.
Cell Biochemistry and Biophysics | Year: 2012

Primary hepatocarcinoma is the most common type of malignant tumor and a leading cause of cancer mortality. Standard treatment for patients with advanced primary hepatocarcinoma for whom surgery is not recommended includes transcatheter arterial chemoembolization (TACE). Within these patients 44% develop metastasis within 1 year. Thus, understanding the events underlying the recurrent tumors and developing therapies in conjunction with TACE would be of great benefit. Reducing tumor angiogenesis by combining the somatostatin analog octreotide with small doses of heparin is one approach in decreasing metastasis rates by targeting VEGF and heparinase, respectively. Given this, we investigated whether a heparin and octreotide combination treatment administered post-TACE would decrease the tumor metastasizing rate in primary hepatocarcinoma. A total of 147 patients diagnosed with primary hepatocarcinoma were admitted to the study and received 2-4 TACE treatments and were monitored for 1 year. Of these 84 received the heparin plus octreotide combination treatment and 63 did not (control group). All patients were monitored for adverse reactions, coagulation ability, and tumor metastasis. We found a significant decrease in the incidence of tumor metastasis in patients receiving the combination treatment post-TACE for up to 1 year with no significant toxic or adverse effects. Thus, we propose using the combination treatment of heparin and octreotide post-TACE in the treatment of recurrent tumorigenesis in primary hepatocarcinoma. © 2011 Springer Science+Business Media, LLC.

Pingsheng F.,The Anhui Tumor Hospital | Tengyue Z.,The Anhui Tumor Hospital | Qiang H.,The Provincial Hospital of Anhui | Qiang W.,The Anhui Tumor Hospital | And 2 more authors.
Cell Biochemistry and Biophysics | Year: 2012

The aim of this study was assess the therapeutic effect of targeted intra-arterial verapamil infusion in liver cancer patients and its side-effects in a dog model. The blood verapamil levels in dogs were determined after one-off intra-arterial infusion (0.7 mg/kg). Blood pressure, breathing state, and II-lead electrocardiogram were measured. Primary liver cancer patients (100) were randomly assigned into two groups. Controls (50) were treated with targeted intra-arterial infusion, and every patient received once-a-month interventional therapy, twice. Treatment group (50) received chemotherapeutics plus verapamil. Therapeutic and toxic side effects were evaluated. Control (41) and treatment group (45) patients were further treated with a second round of targeted intra-arterial infusion of chemotherapeutics plus verapamil, in 30 days after the 2-time interventional therapy. Every patient accepted interventional therapy 4-5 times during the 6 months after the first confirmed diagnosis. Following verapamil infusion, verapamil in dog liver was tenfold higher than in blood and was 4- to 20-fold higher than that needed for reversing carcinoma drug resistance. After interventional therapy, there were no significant changes in iconographic evaluation indices between the groups. Average activities of aminotransferases were 332 and 178 U/l in the treatment and control groups (P < 0.05). The imaging parameters of the treatment group were significantly better than those of control group. No side effects were found among the 91 patients who accepted verapamil infusion. After verapamil infusion, verapamil levels in dog hepatic tissue exceeded the effective concentration that reverses carcinoma multidrug resistance without any visible changes in the vital signs. Targeted intra-arterial verapamil infusion could improve the chemotherapy for the primary liver cancer patients without any side effects. © 2011 Springer Science+Business Media, LLC.

Yu J.-W.,Anhui University | Hao J.-Q.,Anhui University | Hu Z.-G.,The Provincial Hospital of Anhui | Qian L.-T.,The Provincial Hospital of Anhui
Academic Journal of Second Military Medical University | Year: 2016

Objective To compare the thcrapcutic effects and adverse reaction of concurrent chemoradiotherapy with pure chemotherapy for local progressive gastric cancer following D2 lymph node dissection. Methods Seventy-nine patients with progressive gastric cancer who underwent RO gastric resection and D2 lymph node dissection were randomly divided into two groups. After radical gastrectomy, the experimental group (n = 40) received radiotherapy concurrent with capecitabine chemotherapy, and then followed by 4 cycles of XELOX chemotherapy; however, the control group (n = 39) only received 6 cyclcs of XELOX chemotherapy. The local recurrence rates, 3-year disease-free survival rates, 3-year ovcrall survival rates and adverse reactions were evaluated after the treatment. Resulte The local recurrence rate in the experimental group was significantly lower than that of the control group (40. 0%[16/40] vs 64. 1% [25/39],P=0. 032). The 3-year disease-free survival rates and 3-year overall survival rates of the experimental group were higher than those in the control group, but with no significant difference (P> 0. 05). The 3 year overall survival rate of patients with positive lymph node was significantly higher in the experimental group than in the control group (45. 2% [14/31] vs 18. 5% [5/27], P=0. 049), with their median disease-free survival (mDFS)periods being 26 months and 19 months, respectively (P = 0. 024). The incidences of hematological and gastrointestinal toxicities in the experimental group were higher than those in the control group. Concllision Concurrent chemoradiotherapy and chemotherapy can greatly reducc local recurrence after curative resection and D2 lymph node dissection in gastric cancer patients. In patients with lymph node positive gastric cancer, postoperative concurrent chemoradiotherapy may improve their survival. The main adverse reactions of the concurrent treatment are hematological and gastrointestinal toxicities. © 2016, Second Military Medical University Press. All right reserved.

Liu Y.,Anhui Tumor Hospital | Lu Z.,Anhui Tumor Hospital | Fan P.,Anhui Tumor Hospital | Duan Q.,Anhui Tumor Hospital | And 6 more authors.
Cell Biochemistry and Biophysics | Year: 2011

In order to determine the clinical efficacy and adverse reactions of chemotherapy and verapamil infusion through a target artery to treat colorectal cancer patients with metastasis after failure with previous conventional treatments. Patients with metastatic colon cancer (n = 36) received an infusion of verapamil, interleukin-2, oxaliplatin (or hydroxy camptothecin or irinotecan hydrochloride), fluorouracil and calcium folinate through target artery using the Seldinger puncture technique. From the second day of infusion, the patients were treated with fluorouracil and calcium folinate via systematic intravenous injection for 2-3 days. Efficacy was evaluated after at least two treatment courses. The objective response including complete or partial response was 58. 3% in the 36 patients; clinical benefit rate, evaluated by Karnofsky Performance Status score was 91. 7%; by weight was 83. 3%; by the amount of painkiller consumed was 80. 6%. No patient experienced side effects associated with heart function. Post-treatment, the P-R period, Q-T period, QRS, and heart rate were not significantly different than before treatment. Liver function was significantly improved. Side effects of chemotherapy were minor in comparison to those observed with intravenous chemotherapy. Infusion of verapamil and chemotherapy directly into pelvic tumor tissue can increase treatment efficacy and has been shown to be a relatively safe technique. © 2011 Springer Science+Business Media, LLC.

Huang J.,Anhui Tumour Hospital | Duan Q.,Anhui Tumour Hospital | Fan P.,Anhui Tumour Hospital | Ji C.,The Provincial Hospital of Anhui | And 4 more authors.
Cell Biochemistry and Biophysics | Year: 2011

This study evaluates the clinical effectiveness of targeted arterial infusion of verapamil in interventional treatment of primary hepatocellular carcinoma. For this purpose, in 273 patients with middle- or late-stage primary hepatocellular carcinoma, verapamil, IL-2, and chemotherapeutic agents were infused into the target tumor vasculature through femoral artery using Seldinger technique. The medications were infused as serial dilutions, and effectiveness was evaluated after two treatment cycles. Among these 273 patients, 76 cases showed clinical cure or significant improvement, 119 cases improved, 64 cases stabilized, while 14 cases progressed or deteriorated. In 238 patients, KPS score and body weights were stabilized. Regarding side effects, 99 patients (36.3%) developed leukopenia; 160 patients had gastrointestinal reactions (58.6%); 80 patients (29.3%) presented with elevated ALT/AST profile; and 65 cases (23.8%) had pyrexia; however, these side effects abated quickly. No elevations in BUN/Cr and/or allergic reactions were observed. Pre- and post-intervention cardiac function did not change in all the patients. No significant change was observed in ECG. Liver function was also improved after two cycles of treatment. It was concluded that verapamil management via targeted arterial infusion could effectively reverse the multidrug resistance in cancer cells in primary hepatocellular carcinoma patients and therefore enhanced the efficacy of chemotherapy. © 2010 The Author(s).

Discover hidden collaborations